TIMD4 (TIM-4) Drug Discovery Landscape & Assay Solutions

By admin
24 Aug 2026
Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Cell Immunotherapy Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for TIMD4 drug discovery. Select your modality below:

Component / Network	Product Description	Product Link
Antigen	TIMD4 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation).	View TIMD4 Products
Gene Delivery	TIMD4 Lentivirus Particles / Promise-ORF Full-length ORF for stable cell line construction. Ideal for efferocytosis assays.	View TIMD4 Products
Benchmark Ab	Anti-TIMD4 Neutralizing Antibody (Biosimilar Control) Recombinant chimeric antibody for positive control and assay validation.	View TIMD4 Products
Validator	TIMD4 siRNA Set (3 Unique Sequences) For knockdown verification and specificity controls.	View TIMD4 Products
Family Counter-Screen	TIM-3 (HAVCR2) ECD Protein Off-target liability screening for TIM family selectivity.	View HAVCR2 Products
Pathway Partner	MerTK (MERTK) ECD Protein Complementary efferocytosis pathway target; co-blockade strategy.	View MERTK Products
Related Target (CD47)	CD47 Protein Synergistic macrophage phagocytosis checkpoint ("Don't eat me" signal).	View CD47 Products
Related Target (HAVCR2)	TIM-3 (HAVCR2) ECD Protein TIM-family member for specificity counter-screening.	View HAVCR2 Products

Critical Assay Challenges & TarMart Advantage

Critical Assay Challenge	The TarMart Advantage (Technical Spec)
Cross-species cyno/mouse eval for IND-enabling studies	Human/Mouse/Cyno TIMD4 ortholog proteins available with >95% purity; Sequence verified by Mass Spec
TIM family selectivity (TIM-1, TIM-3 off-target)	Homolog panel proteins (TIMD4, TIM-1, TIM-3) with strict sequence divergence verification
Functional efferocytosis validation	Lentivirus Premade Particles for stable HEK293 or THP-1 expression; Native conformation preservation
Phosphatidylserine binding competition	ECD-Fc constructs retain native PS-binding pocket; suitable for blocking assays
Lack of reliable positive controls	Sequence-verified recombinant benchmark antibodies included for binding control
False positives in phagocytosis assays	Validated siRNA included for strict specificity and mechanism-of-action checks

Live TIMD4 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for TIMD4 therapeutics represents a strategic pivot in immuno-oncology toward myeloid cell modulation. As a critical phosphatidylserine receptor expressed on tumor-associated macrophages (TAMs) and dendritic cells, TIMD4 inhibition aims to disrupt the "eat-me" signal shield that tumors exploit to evade immune clearance. Blocking the phosphatidylserine (PS)-TIMD4 axis prevents tumor-associated macrophages from clearing apoptotic cells in a way that induces immunosuppression. Current development focuses predominantly on blocking antibodies to reverse immunosuppressive tumor microenvironments (TME), with emerging interest in TIMD4-directed ADCs and bispecific antibodies (e.g., TIMD4 x CD47). As first-generation TIMD4 antagonists enter Phase I, differentiation will hinge on precise epitope selection—balancing PS-binding disruption against Fc-mediated effector function—and the ability to combine with existing PD-1/PD-L1 inhibitors to overcome resistance in solid tumors. The next wave of R&D is heavily targeting combination therapies and engineered bispecifics, with emerging interest in cell therapy (engineered macrophages) as a novel modality.

Competitive Modality & Indication Snapshot

Modality	Representative Players	Key Indications	Critical Assay Need (Why TarMart?)
Blocking Antibody	Preclinical Biotechs, Academic Labs, Spin-offs	Solid Tumors (TME modulation)	PS-Binding Competition Assay (Need high-purity ECD-Fc with intact binding pocket; strict Endotoxin control)
ADC	Emerging Programs	Macrophage-rich Cancers	Internalization Assay (Need full-length Lentivirus for native conformation)
Bispecific (TIMD4 x CD47)	Preclinical Innovators	Refractory Cancers, Hematologic Malignancies	Heterodimer Validation (Need cross-reactive Abs and dual-antigen panels)
Small Molecule	Fragment-based Discovery	Autoimmune (Efferocytosis Enhancement)	Surface Plasmon Resonance (Need stable immobilized ECD proteins)
Cell Therapy (Engineered Macrophages)	Next-gen Cell Therapy Companies	Solid Tumors	Cellular Phenotype Assays (Need reliable Lentivirus for stable expression/knockdown)